Literature DB >> 27580687

Acute severe ulcerative colitis: from pathophysiology to clinical management.

Pieter Hindryckx1,2,3, Vipul Jairath4,3, Geert D'Haens2,3.   

Abstract

Ulcerative colitis is a common chronic inflammatory disease of the colon and rectum, resulting from a dysregulated immune response towards intraluminal antigens in a genetically predisposed host. The disease has a varying extent and severity. Approximately 20% of patients with ulcerative colitis experience a severe flare during the course of their disease, requiring hospitalization. Acute severe ulcerative colitis (ASUC) is potentially a life-threatening condition that requires early recognition, hospitalization, correction of body fluids and electrolytes, and nutritional support if needed. Superimposed bacterial or viral infections need to be excluded and thromboprophylaxis should be started. Intravenous corticosteroids are the first-line treatment for this condition. Rescue treatment with ciclosporin or infliximab is indicated in patients who do not sufficiently respond to corticosteroids after 3-5 days, with close monitoring of the patients' symptoms, serum C-reactive protein and albumin levels. If medical therapy fails, timely colectomy should be performed to prevent critical complications. In this article, we review all relevant aspects of ASUC, from its pathophysiological background to modern management in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27580687     DOI: 10.1038/nrgastro.2016.116

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  113 in total

1.  Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

Authors:  J H BARON; A M CONNELL; T G KANAGHINIS; J E LENNARD-JONES; A F JONES
Journal:  Br Med J       Date:  1962-08-18

Review 2.  Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?

Authors:  Neeraj Narula; Michael Fine; Jean-Frederic Colombel; John K Marshall; Walter Reinisch
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

3.  ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach.

Authors:  G-T Ho; N Soranzo; E R Nimmo; A Tenesa; D B Goldstein; J Satsangi
Journal:  Hum Mol Genet       Date:  2006-01-24       Impact factor: 6.150

4.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

5.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

6.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

7.  Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

Authors:  G T Ho; H M Lee; G Brydon; T Ting; N Hare; H Drummond; A G Shand; D C Bartolo; R G Wilson; M G Dunlop; I D Arnott; J Satsangi
Journal:  Am J Gastroenterol       Date:  2009-02-17       Impact factor: 10.864

8.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

Authors:  W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

9.  Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.

Authors:  Joris Arts; Geert D'Haens; Miranda Zeegers; Gert Van Assche; Martin Hiele; André D'Hoore; Freddy Penninckx; Severine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-03       Impact factor: 5.325

10.  An antibiotic-responsive mouse model of fulminant ulcerative colitis.

Authors:  Silvia S Kang; Seth M Bloom; Lyse A Norian; Michael J Geske; Richard A Flavell; Thaddeus S Stappenbeck; Paul M Allen
Journal:  PLoS Med       Date:  2008-03-04       Impact factor: 11.069

View more
  30 in total

Review 1.  Contemporary Medical Management of Acute Severe Ulcerative Colitis.

Authors:  Kaitlin G Whaley; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

2.  Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study.

Authors:  Priti Poojary; Aparna Saha; Kinsuk Chauhan; Priya Simoes; Bruce E Sands; Judy Cho; Thomas Ullman; Girish Nadkarni; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2017-03       Impact factor: 5.325

3.  Strictosamide alleviates the inflammation in an acute ulcerative colitis (UC) model.

Authors:  Qinghui Jia; Haihua Zhang; Yongmei Su; Xin Liu; Jiangsong Bai; Wuying Lang; Qiumei Shi; Minshan Feng
Journal:  J Physiol Biochem       Date:  2021-02-17       Impact factor: 4.158

4.  Identification of diagnostic signatures in ulcerative colitis patients via bioinformatic analysis integrated with machine learning.

Authors:  Jiajie Lu; Zhiyuan Wang; Munila Maimaiti; Wenjia Hui; Adilai Abudourexiti; Feng Gao
Journal:  Hum Cell       Date:  2021-11-03       Impact factor: 4.174

5.  AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.

Authors:  Siddharth Singh; Jessica R Allegretti; Shazia Mehmood Siddique; Jonathan P Terdiman
Journal:  Gastroenterology       Date:  2020-01-13       Impact factor: 22.682

6.  Quyushengxin Formula Causes Differences in Bacterial and Phage Composition in Ulcerative Colitis Patients.

Authors:  Haojie Yang; Dan Gan; Ying Li; Xiaosu Wang; Lei Jin; Kaijian Qin; Can Cui; Jiong Wu; Zhenyi Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-11       Impact factor: 2.629

7.  The expression analysis of Fra-1 gene and IL-11 protein in Iranian patients with ulcerative colitis.

Authors:  Milad Sabzevary-Ghahfarokhi; Mojtaba Shohan; Hedayatollah Shirzad; Ghorbanali Rahimian; Nader Bagheri; Amin Soltani; Fatemeh Deris; Mahdi Ghatreh-Samani; Ehsan Razmara
Journal:  BMC Immunol       Date:  2018-06-18       Impact factor: 3.615

8.  A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy.

Authors:  Abhinav Vasudevan; Asiri Arachchi; Cian Scanlon; Jarrod Greenhalgh; Daniel R Van Langenberg
Journal:  Ther Adv Chronic Dis       Date:  2019-01-29       Impact factor: 5.091

9.  Glucocorticoids Promote the Onset of Acute Experimental Colitis and Cancer by Upregulating mTOR Signaling in Intestinal Epithelial Cells.

Authors:  Zhengguo Zhang; Lin Dong; Anna Jia; Xi Chen; Qiuli Yang; Yufei Wang; Yuexin Wang; Ruichen Liu; Yejin Cao; Ying He; Yujing Bi; Guangwei Liu
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

Review 10.  Perioperative Care of Patients with Inflammatory Bowel Disease: Focus on Nutritional Support.

Authors:  Patrick L Stoner; Amir Kamel; Fares Ayoub; Sanda Tan; Atif Iqbal; Sarah C Glover; Ellen M Zimmermann
Journal:  Gastroenterol Res Pract       Date:  2018-09-23       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.